| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $2,233,671 ) |
| | 2025 | 2025 | EICOSIS LLC | 1930 5TH ST STE A | DAVIS | CA | 95616-4018 | YOLO | USA | UH3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 4 | NIH | 1/8/2025 | $2,233,671 |
|
| Issue Date FY: 2024 ( Subtotal = $2,141,943 ) |
| | 2024 | 2024 | EICOSIS LLC | 1930 5TH ST STE A | DAVIS | CA | 95616-4018 | YOLO | USA | UH3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 001 | 3 | NIH | 2/1/2024 | -$2,141,943 |
| | 2024 | 2024 | EICOSIS LLC | 1930 5TH ST STE A | DAVIS | CA | 95616-4018 | YOLO | USA | UH3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 003 | 3 | NIH | 9/27/2024 | $0 |
| | 2024 | 2024 | EICOSIS LLC | 1930 5TH ST STE A | DAVIS | CA | 95616-4018 | YOLO | USA | UH3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 3 | NIH | 12/18/2023 | $2,141,943 |
| | 2024 | 2024 | EICOSIS LLC | 1930 5TH ST STE A | DAVIS | CA | 95616-4018 | YOLO | USA | UH3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 001 | 3 | NIH | 2/1/2024 | $2,141,943 |
| | 2024 | 2024 | EICOSIS LLC | 1930 5TH ST STE A | DAVIS | CA | 95616-4018 | YOLO | USA | UH3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 002 | 3 | NIH | 7/18/2024 | $2,141,943 |
| | 2024 | 2024 | EICOSIS LLC | 1930 5TH ST STE A | DAVIS | CA | 95616-4018 | YOLO | USA | UH3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 002 | 3 | NIH | 7/18/2024 | -$2,141,943 |
| | 2024 | 2022 | EICOSIS LLC | 1930 5TH ST STE A | DAVIS | CA | 95616-4018 | YOLO | USA | R43HL164226 | Identification of mechanism-based therapies to treat arrhythmogenic cardiomyopathy by resolving perturbations in regulatory lipid signaling | 000 | 1 | NIH | 4/19/2024 | $0 |
| | 2024 | 2020 | EICOSIS LLC | 1930 5TH ST STE A | DAVIS | CA | 95616-4018 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 001 | 2 | NIH | 10/13/2023 | $0 |
| | 2024 | 2020 | EICOSIS LLC | 1930 5TH ST | DAVIS | CA | 95616-4018 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 2 | NIH | 10/11/2023 | $0 |
| | 2024 | 2020 | EICOSIS LLC | 1930 5TH ST | DAVIS | CA | 95616-4018 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 2 | NIH | 10/11/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2020 | EICOSIS LLC | 1930 5TH ST | DAVIS | CA | 95616-4018 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 2 | NIH | 12/7/2022 | $0 |
| | 2023 | 2020 | EICOSIS LLC | 1930 5TH ST | DAVIS | CA | 95616-4018 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 2 | NIH | 12/7/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $279,136 ) |
| | 2022 | 2022 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | R43HL164226 | Identification of mechanism-based therapies to treat arrhythmogenic cardiomyopathy by resolving perturbations in regulatory lipid signaling | 000 | 1 | NIH | 6/30/2022 | $279,136 |
| | 2022 | 2022 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | R43HL164226 | Identification of mechanism-based therapies to treat arrhythmogenic cardiomyopathy by resolving perturbations in regulatory lipid signaling | 001 | 1 | NIH | 8/5/2022 | $0 |
| | 2022 | 2020 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 2 | NIH | 8/3/2022 | $0 |
| | 2022 | 2020 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 2 | NIH | 8/3/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = -$1,327 ) |
| | 2021 | 2020 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 2 | NIH | 6/11/2021 | $0 |
| | 2021 | 2020 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 2 | NIH | 6/11/2021 | $0 |
| | 2021 | 2019 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | R43CA233371 | Inhibiting soluble epoxide hydrolase as a treatment for chemotherapy inducedperipheral neuropathic pain | 000 | 1 | NIH | 7/2/2021 | -$1,327 |
|
| Issue Date FY: 2020 ( Subtotal = $3,046,512 ) |
| | 2020 | 2020 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 002 | 2 | NIH | 8/19/2020 | $3,046,519 |
| | 2020 | 2020 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 003 | 2 | NIH | 9/22/2020 | -$2,419,751 |
| | 2020 | 2020 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 003 | 2 | NIH | 9/22/2020 | $2,419,751 |
| | 2020 | 2019 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 001 | 1 | NIH | 8/18/2020 | $0 |
| | 2020 | 2019 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 1 | NIH | 12/11/2019 | $0 |
| | 2020 | 2019 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | R43CA233371 | Inhibiting soluble epoxide hydrolase as a treatment for chemotherapy inducedperipheral neuropathic pain | 000 | 1 | NIH | 10/30/2019 | $0 |
| | 2020 | 2017 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | R44ES025598 | sEH Inhibitors to Treat Neuropathic Pain | 000 | 3 | NIH | 1/16/2020 | -$7 |
|
| Issue Date FY: 2019 ( Subtotal = $3,298,305 ) |
| | 2019 | 2019 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | R43CA233371 | Inhibiting soluble epoxide hydrolase as a treatment for chemotherapy inducedperipheral neuropathic pain | 000 | 1 | NIH | 9/25/2019 | $268,196 |
| | 2019 | 2019 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UG3DA048767 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | 000 | 1 | NIH | 9/27/2019 | $3,036,135 |
| | 2019 | 2017 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UH3NS094258 | Development of an Oral Analgesic for Neuropathic Pain | 001 | 2 | NIH | 9/5/2019 | -$6,026 |
| | 2019 | 2017 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UH3NS094258 | Development of an Oral Analgesic for Neuropathic Pain | 000 | 2 | NIH | 9/4/2019 | $3,187 |
| | 2019 | 2016 | EICOSIS, LLC | 25242 COUNTY ROAD 95 | DAVIS | CA | 95616-9405 | YOLO | USA | UH2NS094258 | Development of an Oral Analgesic for Neuropathic Pain | 000 | 1 | NIH | 9/4/2019 | -$3,187 |
|
| Issue Date FY: 2017 ( Subtotal = $831,756 ) |
| | 2017 | 2017 | EICOSIS, LLC | 1407 NUTMEG LN | DAVIS | CA | 95618-1419 | YOLO | USA | UH3NS094258 | Development of an Oral Analgesic for Neuropathic Pain | 000 | 2 | NIH | 5/5/2017 | $125,246 |
| | 2017 | 2017 | EICOSIS, LLC | 1407 NUTMEG LN | DAVIS | CA | 95618-1419 | YOLO | USA | R44ES025598 | sEH Inhibitors to Treat Neuropathic Pain | 001 | 3 | NIH | 5/19/2017 | $1,382 |
| | 2017 | 2017 | EICOSIS, LLC | 1407 NUTMEG LN | DAVIS | CA | 95618-1419 | YOLO | USA | R44ES025598 | sEH Inhibitors to Treat Neuropathic Pain | 000 | 3 | NIH | 2/28/2017 | $705,128 |
| | 2017 | 2016 | EICOSIS, LLC | 1407 NUTMEG LN | DAVIS | CA | 95618-1419 | YOLO | USA | UH2NS094258 | Development of an Oral Analgesic for Neuropathic Pain | 000 | 1 | NIH | 5/3/2017 | $0 |
| | 2017 | 2016 | EICOSIS, LLC | 1407 NUTMEG LN | DAVIS | CA | 95618-1419 | YOLO | USA | UH2NS094258 | Development of an Oral Analgesic for Neuropathic Pain | 001 | 1 | NIH | 5/4/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $1,082,132 ) (Continued on the next page) |
| | 2016 | 2016 | EICOSIS, LLC | 1407 NUTMEG LN | DAVIS | CA | 95618 | YOLO | USA | UH2NS094258 | Development of an Oral Analgesic for Neuropathic Pain | 000 | 1 | NIH | 12/15/2015 | $224,163 |
| | 2016 | 2016 | EICOSIS, LLC | 1407 NUTMEG LN | DAVIS | CA | 95618 | YOLO | USA | R44ES025598 | sEH Inhibitors to Treat Neuropathic Pain | 001 | 2 | NIH | 9/9/2016 | $76,094 |
| | 2016 | 2016 | EICOSIS, LLC | 1407 NUTMEG LN | DAVIS | CA | 95618 | YOLO | USA | R44ES025598 | sEH Inhibitors to Treat Neuropathic Pain | 000 | 2 | NIH | 2/25/2016 | $731,876 |
| | 2016 | 2016 | EICOSIS, LLC | 1407 NUTMEG LN | DAVIS | CA | 95618 | YOLO | USA | UH2NS094258 | Development of an Oral Analgesic for Neuropathic Pain | 001 | 1 | NIH | 7/15/2016 | $49,999 |
|
